Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on ...

The AHA is expanding its initiative to improve detection, standardize care, and enhance treatment for hypertrophic cardiomyopathy.

Final Decision from European Commission Expected in Q1 2026SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- Cytokinetics, ...

Hypertrophic cardiomyopathy, also known as HCM, is the most common genetic heart condition and can affect the heart’s structure and function, causing the walls of the heart muscle to thicken and ...

Background Dyspnoea and reduced exercise capacity are common features in hypertrophic cardiomyopathy (HCM) without left ...

Hypertrophic cardiomyopathy (HCM) is an underdiagnosed genetic heart condition. Raising awareness through advocacy can help increase the rates of diagnosis and proper management. HCM is when the left ...

Future Cardiol. 2013;9(5):697-709. It is extremely important to detect the presence and severity of LVOT obstruction from physical examination, as well as 2D and Doppler echocardiography. The LVOT ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A small panel of ...

DelveInsight's Gene Therapies for Cardiomyopathies Market Insights report includes a comprehensive understanding of current treatment practices, emerging gene therapies for cardiomyopathies, market ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...